Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

Kathy Miller, Véronique Diéras, Nadia Harbeck, Fabrice Andre, Reshma L. Mahtani, Luca Gianni, Kathy S. Albain, Diana Crivellari, Liang Fang, Glenn Michelson, Sanne L. De Haas, Howard A. Burris

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC). Patients and Methods: Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 weeks. The primary efficacy end point was investigator-assessed objective response rate (ORR). Results: Sixty-four patients (43 patients in the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line MBC]) were enrolled. Patients with advancedMBChad received trastuzumab and a median of six prior nonhormonal treatments for MBC; 86% of first-line MBC patients had received trastuzumab in the (neo)adjuvant setting. The ORR was 41% overall, 33% in patients with advanced MBC, and 57% in first-line patients. Median progression-free survival was 6.6, 5.5, and 7.7 months, respectively. The most common adverse events were fatigue (61%), nausea (50%), and diarrhea (39%). The most frequent grade ≥ 3 adverse events were thrombocytopenia (13%), fatigue (11%), and liver enzyme elevations (increased ALT: 9%; increased AST: 9%). One patient had left ventricular ejection fraction of less than 40% after study drug discontinuation. Exploratory biomarker analyses demonstrated that patients with above-median tumor HER2 mRNA levels had a numerically higher ORR than patients with below-median levels (44% v 33%, respectively). Conclusion: T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.

Original languageEnglish
Pages (from-to)1437-1444
Number of pages8
JournalJournal of Clinical Oncology
Volume32
Issue number14
DOIs
StatePublished - May 10 2014

Fingerprint

Breast Neoplasms
human ERBB2 protein
pertuzumab
ado-trastuzumab emtansine
Fatigue
Thrombocytopenia
Stroke Volume
Nausea
Disease-Free Survival
Diarrhea
Biomarkers
Research Personnel
Safety
Messenger RNA
Liver
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. / Miller, Kathy; Diéras, Véronique; Harbeck, Nadia; Andre, Fabrice; Mahtani, Reshma L.; Gianni, Luca; Albain, Kathy S.; Crivellari, Diana; Fang, Liang; Michelson, Glenn; De Haas, Sanne L.; Burris, Howard A.

In: Journal of Clinical Oncology, Vol. 32, No. 14, 10.05.2014, p. 1437-1444.

Research output: Contribution to journalArticle

Miller, K, Diéras, V, Harbeck, N, Andre, F, Mahtani, RL, Gianni, L, Albain, KS, Crivellari, D, Fang, L, Michelson, G, De Haas, SL & Burris, HA 2014, 'Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer', Journal of Clinical Oncology, vol. 32, no. 14, pp. 1437-1444. https://doi.org/10.1200/JCO.2013.52.6590
Miller, Kathy ; Diéras, Véronique ; Harbeck, Nadia ; Andre, Fabrice ; Mahtani, Reshma L. ; Gianni, Luca ; Albain, Kathy S. ; Crivellari, Diana ; Fang, Liang ; Michelson, Glenn ; De Haas, Sanne L. ; Burris, Howard A. / Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 14. pp. 1437-1444.
@article{8c3cd7a1961d4d438d95ada9d4dee62d,
title = "Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer",
abstract = "Purpose: Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC). Patients and Methods: Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 weeks. The primary efficacy end point was investigator-assessed objective response rate (ORR). Results: Sixty-four patients (43 patients in the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line MBC]) were enrolled. Patients with advancedMBChad received trastuzumab and a median of six prior nonhormonal treatments for MBC; 86{\%} of first-line MBC patients had received trastuzumab in the (neo)adjuvant setting. The ORR was 41{\%} overall, 33{\%} in patients with advanced MBC, and 57{\%} in first-line patients. Median progression-free survival was 6.6, 5.5, and 7.7 months, respectively. The most common adverse events were fatigue (61{\%}), nausea (50{\%}), and diarrhea (39{\%}). The most frequent grade ≥ 3 adverse events were thrombocytopenia (13{\%}), fatigue (11{\%}), and liver enzyme elevations (increased ALT: 9{\%}; increased AST: 9{\%}). One patient had left ventricular ejection fraction of less than 40{\%} after study drug discontinuation. Exploratory biomarker analyses demonstrated that patients with above-median tumor HER2 mRNA levels had a numerically higher ORR than patients with below-median levels (44{\%} v 33{\%}, respectively). Conclusion: T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.",
author = "Kathy Miller and V{\'e}ronique Di{\'e}ras and Nadia Harbeck and Fabrice Andre and Mahtani, {Reshma L.} and Luca Gianni and Albain, {Kathy S.} and Diana Crivellari and Liang Fang and Glenn Michelson and {De Haas}, {Sanne L.} and Burris, {Howard A.}",
year = "2014",
month = "5",
day = "10",
doi = "10.1200/JCO.2013.52.6590",
language = "English",
volume = "32",
pages = "1437--1444",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer

AU - Miller, Kathy

AU - Diéras, Véronique

AU - Harbeck, Nadia

AU - Andre, Fabrice

AU - Mahtani, Reshma L.

AU - Gianni, Luca

AU - Albain, Kathy S.

AU - Crivellari, Diana

AU - Fang, Liang

AU - Michelson, Glenn

AU - De Haas, Sanne L.

AU - Burris, Howard A.

PY - 2014/5/10

Y1 - 2014/5/10

N2 - Purpose: Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC). Patients and Methods: Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 weeks. The primary efficacy end point was investigator-assessed objective response rate (ORR). Results: Sixty-four patients (43 patients in the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line MBC]) were enrolled. Patients with advancedMBChad received trastuzumab and a median of six prior nonhormonal treatments for MBC; 86% of first-line MBC patients had received trastuzumab in the (neo)adjuvant setting. The ORR was 41% overall, 33% in patients with advanced MBC, and 57% in first-line patients. Median progression-free survival was 6.6, 5.5, and 7.7 months, respectively. The most common adverse events were fatigue (61%), nausea (50%), and diarrhea (39%). The most frequent grade ≥ 3 adverse events were thrombocytopenia (13%), fatigue (11%), and liver enzyme elevations (increased ALT: 9%; increased AST: 9%). One patient had left ventricular ejection fraction of less than 40% after study drug discontinuation. Exploratory biomarker analyses demonstrated that patients with above-median tumor HER2 mRNA levels had a numerically higher ORR than patients with below-median levels (44% v 33%, respectively). Conclusion: T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.

AB - Purpose: Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC). Patients and Methods: Patients with HER2-positive locally advanced breast cancer or MBC were treated with 3.6 mg/kg T-DM1 plus pertuzumab (840-mg loading dose, then 420 mg subsequently) once every 3 weeks. The primary efficacy end point was investigator-assessed objective response rate (ORR). Results: Sixty-four patients (43 patients in the second-line or greater setting [advanced MBC]; 21 patients in the first-line setting [first-line MBC]) were enrolled. Patients with advancedMBChad received trastuzumab and a median of six prior nonhormonal treatments for MBC; 86% of first-line MBC patients had received trastuzumab in the (neo)adjuvant setting. The ORR was 41% overall, 33% in patients with advanced MBC, and 57% in first-line patients. Median progression-free survival was 6.6, 5.5, and 7.7 months, respectively. The most common adverse events were fatigue (61%), nausea (50%), and diarrhea (39%). The most frequent grade ≥ 3 adverse events were thrombocytopenia (13%), fatigue (11%), and liver enzyme elevations (increased ALT: 9%; increased AST: 9%). One patient had left ventricular ejection fraction of less than 40% after study drug discontinuation. Exploratory biomarker analyses demonstrated that patients with above-median tumor HER2 mRNA levels had a numerically higher ORR than patients with below-median levels (44% v 33%, respectively). Conclusion: T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84902973417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902973417&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.52.6590

DO - 10.1200/JCO.2013.52.6590

M3 - Article

VL - 32

SP - 1437

EP - 1444

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -